Clinical pancreatology I: Pancreatic medical history

Åke Andrén-Sandberg

Department of Surgery
Karolinska Institute at Karolinska University Hospital, Huddinge, Stockholm, Sweden.

Citation: Andrén-Sandberg Å. Clinical pancreatology I: Pancreatic medical history. North Am J Med Sci 2010; 2: 502-509.
Doi: 10.4297/najms.2010.2502
Availability: www.najms.org
ISSN: 1947 – 2714

Abstract
The present article and subsequent reviews will not be to report all what has been published, but rather to give an introduction samples that hopefully make the reader eager to read the whole article or articles with “a taste of clinical pancreatology in 2010”. The main sources of literatures were PubMed, and the additional Journals such as Pancreas, Pancreatology and Journal of the Pancreas were also scrutinized. Only some full articles in almost all languages were included in the review, other articles, however, that were too superficial or too poor in other ways, were omitted, and the publications of non-human study were excluded.

Keywords: Pancreas, Billroth, stomach, pancreatitis, minimizing toxicity, peritoneal lavage, autodigestion, acute

Correspondence to: Andrén-Sandberg Å. Department of Surgery, Karolinska Institute at Karolinska University Hospital, Huddinge, SE-141 86 Stockholm, Sweden.

German Contributions
Throughout much of history, surgery of the pancreas was restricted to drainage of abscesses and treatment of traumatic wounds. At the turn of the 20th century under the impetus of anesthesia, such surgical stalwarts as Mayo Robson, von Mickulicz, and Sir Moynihan began to deploy laparotomy and gauze drainage in an effort to salvage patients afflicted with severe acute pancreatitis.

After the routine use of ether narcosis and surgical antisepsis, the evolution of surgery experienced fascinating and genuinely surgical technique-related advancements. Surgeons from Germany contributed strongly to the upturn of operative treatment in the second half of the nineteenth century. B von Langenbeck inaugurated in 1852 an osteosynthese device in a patient with pseudoarthrosis and opened up surgery also for softer areas. He is credited to be the very first in introducing the principle of fixateur externe. Theodor Billroth performed in 1873 the first extirpation of the larynx in a patient with a malignant tumor. Postoperatively, the patient was cared with an artificial larynx. The first successful resection of the distal stomach was also inaugurated by Billroth, in 1881, and was later called the Billroth II procedure. Rydygier from Kulm and Billroth from Wien are the first who successfully performed resection of the lower part of the stomach with anastomosis to the duodenum (Billroth I type of resection). In 1883, Theodor Kocher from Bern reported 101 cases of thyroidectomy, the largest single-surgeon experience. L. Rehn from Frankfurt did in 1887 the first successful suturing of a beating heart to repair a large stab wound. A. Braun, Königsberg, presented in 1892 his techniques of side-to-side anastomosis of the intestine to avoid a circular intestinal anastomosis. F. Sauerbruch from Breslau published in 1904 his thoracotomy chamber with space for two surgeons opening routine access to intrathoracic tissues protecting pulmonary ventilation during surgery. Walter Kausch from Berlin reported in 1912 about three successful pancreatic head resections for peripapillary cancer. The first successful pancreatic head resection was performed in 1909 in a patient with a cancer of the papilla. The patient survived for a long term [1].

Over the next thirty years, surgical intervention in severe pancreatitis became the therapy for choice, despite surgical mortality rates that often exceeded 50 percent. When the discovery of the serum test for amylase revealed that clinically milder forms of acute pancreatitis existed that
could respond to nonoperative therapy, a wave of conservatism emerged. For the next quarter century, surgical intervention for severe acute pancreatitis was rarely practiced. However, by the 1960s, conservative mortality rates for severe pancreatitis were reported to be as high as 60 to 80 percent, leading surgeons to not only refine the indications for surgery in severe acute pancreatitis, but also to consider new approaches. Extensive pancreatic resections for severe pancreatitis became the vogue in continental surgical centers in the 1960s and 1970s, but often resulted in high mortality rates and inadvertent removal of viable tissue. Accurate diagnosis of pancreatic necrosis by dynamic CT led to new approaches for management. Some surgeons recommended restricting intervention to those with documented infected necrosis, and proposed delayed exploration employing sequestrectomy and open-packaging. Others advocated debridement early in the course of the disease for all patients with necrotizing pancreatitis, regardless of the status of infection. In the 1990s, however, a series of prospective studies emerged proving that nonoperative management of patients with sterile pancreatic necrosis was superior to surgical intervention, and that delayed intervention provided improved surgical mortality rates. The surgical odyssey in managing the necrotizing form of severe acute pancreatitis, from simple drainage, to resection, to debridement, to sequestrectomy, although somewhat tortuous, is nevertheless a notable example of how evidence-based knowledge leads to improvement in patient care. Today's 10 to 20 percent surgical mortality rates reflect not only considerable advances in surgical management, but also highlight concomitant improvements in fluid therapy, antibiotics, and intensive care. Although history documents the important contributions that surgical practitioners have made to acute pancreatitis and its complications, surgeons are rarely complacent, and the recent emergence of minimally invasive techniques holds future promise for patients afflicted with this "... most formidable of catastrophes" [2].

Acute pancreatitis in 20th century
The treatment of acute pancreatitis is based in decades long past but still have impact on the therapy of this disease today. The history identifies in retrospect the correct avenues of research and the blind alleys, and describes the ebb and flow of interest in various forms of management. Acquaintance with the work of previous investigators [3-5] may prevent the unnecessary rediscovery of old principles of treatment.

Principle of minimizing toxicity
It was clear from the outset that acute pancreatitis can be divided into the relatively harmless edematous or interstitial form and the initially often fatal necrotizing form. The necroses were thought to have a toxic effect on the course of the disease. However, the diagnosis of acute pancreatitis was very difficult. In the absence of laboratory tests and imaging procedures, clinical examination was crucial. Diagnostic pointers were a history of biliary colic, obesity, occurrence of the first symptoms after consumption of a large meal, severe cyanosis, and possibly hematemesis. Acute pancreatic necrosis was confirmed by the presence of initial shock [6], so the diagnosis became clear only late in the disease course. Once acute necrotizing pancreatitis had been diagnosed with the aid of the few means at hand, it was considered absolutely necessary to operate immediately and remove the necroses. The surgical treatment initially comprised opening the abdominal cavity to drain off an exudate [7]; it was only later that surgical interventions were performed on the pancreas itself.

One of the first to recommend surgical intervention for pancreatitis was the Chicago surgeon Nicholas Senn [8] cited by Rocha et al [9]. At that time, in the 1880s, pancreatitis was believed to be the response of the pancreas to duodenal disease. Senn recommended drainage and removal of all necrotic tissue. In what was probably the largest study of the time, Schmieden and Sebening [10] reported on 1,278 patients with acute pancreatitis, of whom 654 died, representing a mortality of 51 percent. The authors recommended operation over observation, but described the pancreas as an organ inimical to surgery. Right up to the 1940s, the main cause of death in acute pancreatitis was circulatory shock, undoubtedly a consequence of ignorance of the modern principles of intensive care medicine [11]. Even then, however, some voices warned against operating unnecessarily [12]. Morton [13] found that patients with interstitial pancreatitis, then known as “acute pancreatic edema”, were best left in peace. If operated upon, 27 percent of them died. Nordmann [6] gained the impression that a surgical procedure accelerated the development of necrotizing pancreatitis; this too was perhaps a consequence of the lack of intensive therapy. Parenchymal necrosis varied from 0 to 100 percent of the resected specimen, although at operation all the glands were considered totally or subtotally necrotic. In other words, a large number of surgeons found it hard to distinguish pancreatic and extrapancreatic necroses intraoperatively. The unsatisfactory results of operative treatment led to a move away from surgery at any price towards active conservative therapy [12]. This achieved the first decisive reductions in mortality. The lowering of the overall mortality of necrotizing pancreatitis from around 50 percent to about 25 percent was a great leap forward [14, 15].

In the 1960s and 1970s, the pendulum swung towards rapid operative intervention after diagnosis, but with distinct differences from country to country. In the UK, Watts [16] was the first to successfully perform resection of the head of the pancreas in hemorrhagic necrotizing pancreatitis. Early resection, right up to total pancreatectomy, was also recommended in France [17-20]. In Germany, the Mainz group first advised early operation, i.e. necrosectomy soon after admission [21], and later recommended delayed surgery in order to be able to at least approximately demarcate the necroses [22]. In the middle of the 1980s, Germany and many other countries followed the indications for surgical management and surgical goals formulated by Beger and his group [23]. The principles of
intensive care medicine began to become established. With regard to the pancreas, generous administration of fluids, particularly of human albumin, was a breakthrough [24, 25].

**Peritoneal lavage**

Corresponding with general clinical experience, it was observed that patients with acute pancreatitis and severe abdominal pain became pain-free immediately after the beginning of peritoneal lavage. This gave rise to the idea that toxic substances could be removed by means of lavage, and thus that lavage could represent a treatment not only for renal insufficiency (a complication of acute pancreatitis), but also for pancreatitis itself. Following the development of a dialysis procedure applicable to rats [26], continuous peritoneal dialysis performed as a treatment for acute experimental taurocholate pancreatitis in the rat significantly prolonged the mean duration of survival and reduced the mortality rate of this experimental disease [27]. Pancreatic ascites fluid given intravenously led to a sharp decrease in blood pressure in healthy dogs [28, 29]. The reason for this effect was unknown, but it was proposed to be partly due to histamine [30, 31]. In a similar experiment, ascites fluid given intraperitoneally also led to a decrease in blood pressure [32]. No follow-up studies were conducted to identify which toxic substance(s) actually led to the fall in blood pressure.

Eight randomized prospective clinical trials evaluating the influence of continuous peritoneal lavage in patients with acute pancreatitis were performed, but led to divergent results [33-40]. A meta-analysis, however, showed that this therapeutic procedure was not associated with any improvement in mortality or morbidity [41]. Furthermore, attempts were made to enhance the efficacy of peritoneal lavage by adding protease inhibitors to the lavage solution. However, neither of two clinical randomized trials showed any significant differences in mortality and morbidity [42, 43].

**Principle of inhibition of secretion**

Putting the pancreas at rest in acute pancreatitis became a cardinal principle in the 1960s and 1970s. The goal was either to inhibit gastric secretion, thereby indirectly influencing pancreatic secretion, or to inhibit pancreatic secretion directly.

Following reports of possible triggering of acute pancreatitis by cimetidine in the 1970s [44], animal experiments were carried out to ascertain whether this H₂ receptor antagonist could be harmful. Hadas et al [45] found that cimetidine increased the mortality of sodium taurocholate pancreatitis in rats tenfold. However, these findings could not be duplicated in other animal studies [46, 47]. A meta-analysis carried out several years ago [48] covered five randomized controlled trials written in English comparing the effects of H₂ receptor antagonists with those of placebo [49-53]. This meta-analysis [47] showed that cimetidine was not more effective than placebo in reducing acute pancreatitis-related complications and the duration of pain; rather, the use of cimetidine for acute pancreatitis could be associated with higher rates of complications and pain. Thereafter, inhibition of acid secretion was indicated only in severe acute pancreatitis to prevent bleeding from ulcers.

Atropine inhibits gastric and pancreatic secretions and exerts a spasmylocytic action on the sphincter of Oddi. These properties would seem to make administration of atropine an ideal therapeutic intervention in acute pancreatitis. These effects cannot be achieved, however, with the dosage that can be administered, i.e. 4 × 0.5 mg/24 h. Higher dosages lead to adverse effects such as amplified symptoms of ileus, tachycardias and atropine psychoses; therefore, particularly after the sole controlled study [54] showed no favorable effect of atropine on the course of acute pancreatitis, this substance was no longer employed. Interestingly, very early reports of the complications of acute pancreatitis included pancreatic encephalopathy, but later, when atropine was no longer used, this adverse effect was not mentioned. Perhaps there is no pancreatic encephalopathy, and the complication that was observed was in fact an atropine psychosis.

Glucagon inhibits the ecbolic and to a lesser extent the hydrokinetic pancreatic secretion. After a first report on the action of glucagon in patients with acute pancreatitis seemed to show a beneficial effect [55], numerous other investigations were conducted. One study showed a favorable influence of glucagon on pancreatitis in pig, but this could not be confirmed in other animal models and species [56-60]. Later clinical controlled studies showed no beneficial effect on the course or the mortality of human acute pancreatitis [61-68]. Therefore, the administration of glucagon in acute pancreatitis was abandoned.

Calcitonin, like glucagon, principally inhibits pancreatic enzyme secretion [69]. However, several clinical studies showed no beneficial effect of calcitonin on the course of acute pancreatitis [70-72].

**Principle of inhibition of autodigestion**

After numerous studies had failed to show any significant decrease in the mortality of patients with acute pancreatitis under treatment with aprotinin [73], one team of investigators [74] was able to reduce the mortality rate considerably by administering a high dose of aprotinin in biliary and idiopathic acute pancreatitis. However, these findings were not confirmed in subsequent trials [75].

The failure of aprotinin, the first antiprotease drug to be used in clinical trials, was attributed to the molecular weight of the substance (6,500 Da), which was considered too high to permit uptake in pancreatic acinar cells and thus inhibition of intracellular proteases. A low-molecular-weight antiprotease, gabexate-mesilate (417 Da), was synthesized and showed promise. However, controlled studies found that this substance was not effective in preventing complications and mortality in acute pancreatitis [76-78]. A meta-analysis on the effectiveness
of gabexate-mesilate in acute pancreatitis confirmed that it did not affect mortality or the incidence of complications, including those that required surgery, and thus cannot be recommended [79].

Antifibrinolytics such as epsilon-aminocaproic acid and its derivatives, tranexamic acid, and p-aminomethylbenzoic acid inhibit plasmin and trypsin and also increase the antiproteinase activity of plasma. In a single controlled study, epsilon-aminocaproic acid had no effect on the course of the disease [80].

Treatment of acute pancreatitis with fresh-frozen plasma, given to replenish important circulating proteins, particularly the naturally occurring antiprotease system, seemed to be successful in an uncontrolled study [81]. However, multiple clinical trials of low- and high-volume fresh-frozen plasma therapy showed no differences between treated and nontreated patients [82, 83].

Principle of inhibition of inflammation
Indomethacin inhibits prostaglandin production in vivo and is a very powerful inhibitor of phospholipase A2 activity in serum in patients with acute pancreatitis [84]. In the 1970s, oral or intramuscular administration of indomethacin before or shortly after the triggering of an acute pancreatitis attack in rats markedly reduced mortality [85]. Several years later, in a controlled double-blind study, a Danish group achieved a clear reduction in the frequency and intensity of pain in patients with acute pancreatitis by administering indomethacin suppositories 50 mg twice daily for 7 days [86].

Summary of a century of management of acute pancreatitis
The greatest change in the treatment of acute pancreatitis is that surgery has been transformed from an immediate measure in necrotizing disease to a late intervention. Although large prospective, multicenter studies are still lacking, the pendulum has swung towards conservative treatment: across the world, conservative measures are tried first even in the presence of infected necroses. Surgical intervention is reserved for complications in the later stages of the disease. Peritoneal lavage has been discontinued owing to its lack of clinical efficacy. It is unfortunate that no investigations were carried out to establish which substances are responsible for the hypotensive action of ascites fluid; a new principle of therapy might have emerged. The principle of inhibition of autodigestion has been completely abandoned, at least in most countries. Endoscopic sphincterotomy has an established role, while cholecystectomy to prevent recurrence of biliary pancreatitis is undisputed but is still performed too infrequently [87].

Some stars in the pancreatology in 20th century
Joan Braganza
Dr. Joan Braganza, a world expert in the field of chronic pancreatitis, proposed a new template for its pathogenesis based on the role of free radical pathology, in particular the heightened but unmitigated oxidative detoxification reactions via cytochromes P450. Dr. Braganza has gone on to show how pancreatic damage in cystic fibrosis, acute pancreatitis and pancreatic cancer fit into the scheme, paving the way for new treatment modalities. She graduated in Bombay in 1966, having never seen a patient with chronic pancreatitis, but in January 1968 she found herself in a chronic pancreatitis referral unit at the Manchester Royal Infirmary. Its chief was Henry Howat who had introduced pancreozymin – discovered by Alan Harper and colleagues at the University – as an adjunct in the classical secretin test. The finding of secretory impairment was the only way to diagnose chronic pancreatitis pre-operatively. It was clear that chronic pancreatitis was equated with alcoholism, and that duct decompression or resective surgery was the mainstay of treatment for agonizing pain, in apparent support of the notion that calcifying protein plugs in the duct system were the seminal problem that led to strictures, compromising acinar function. In May 1969, soon after she had obtained the MRCP, domestic tragedy forced her to resign. Howat had an ongoing research program on gastric and pancreatic secretion in the anesthetized cat in response to caerulein analogues. She synthesized the research data into an MSc thesis and wrote four papers for The Journal of Physiology. Her new finding was that Boots secretin – but not the purer gastrointestinal-hormone product from Stockholm – had a potent pepsin-stimulating effect which was not due to a non-specific increase in blood flow, as shown by cannulating the hepatic artery. Howat retired in 1976. Now, with responsibility for some 100 patients with chronic pancreatitis, she switched focus to its etiology. The threefold increase in annual admissions since 1955 was impressive, as was the younger age at presentation. Alcohol was not implicated in 50 percent of the cases. Instead, a threefold increase in the UK consumption of corn oil, essentially linoleic acid, had been documented. In chronic pancreatitis patients, there was a striking excess of copper and also bilirubin soon after secretin, and higher serum levels, too, of caeruloplasmin [88]. The idea that these changes reflected a compensation for excessive copper absorption, in line with a failing pancreas, was supported by rat experiments. The quest for an explanation led to London’s Thomas Dormandy – a pioneer in the field of free radical pathology. In patients with chronic pancreatitis it was found high concentrations in secretin- stimulated bile or duodenal aspirate of several lipid-based products of free radical oxidation [89]. Now, the copper aberrations could be interpreted as indicating the mobilization of hepatic antioxidant defense. Moreover, secretin was known to increase the activity of microsomal cytochromes P450 (CYP) and bilirubin transferases in rat liver. Not only are CYP induced by alcohol and corn oil-rich diets, but they detoxify numerous xenobiotics, in the process generating reactive oxygen species and sometimes, as in paracetamol poisoning, also reactive xenobiotic species. Thus, it was proposed that pancreatic disease – not only chronic pancreatitis but also acute pancreatitis and cancer – may be a casualty of hepatic
“detoxification”, when reactive material enters the gland in refluxed bile or duodenal juice [89]. David Dreiling was the first to see the potential merit of this hypothesis. Pharmacokinetic studies confirmed an induction of CYP – especially the CYP1 family – in the majority of patients, including those with idiopathic disease. This was rationalized by cigarette smoke constituents, but especially, by regular close exposure to occupational volatile hydrocarbons [90, 91]. These would strike the pancreas directly, bypassing the protective liver sieve. Thus, CP – and also drug-related acute pancreatitis and pancreatic cancer – might actually reflect direct oxidant damage via reactivated pancreatic CYP. That could be the reason why surgical diversion of toxic bile failed to abort attacks. Studies of habitual diets in patients with idiopathic chronic pancreatitis, by reference to a CYP1-induced control group on anticonvulsants, underlined their lower intakes of selenium, vitamin C and methionine. These micronutrients interact in the methionine transsulphuration pathway that yields glutathione and other detoxifiers. Several enzymes in this pathway are vulnerable to oxidative stress, as are the components of the signal transduction route towards exocytosis in the pancreatic acinar cell. Pain reduction was accompanied by a fall in serum 9,11,LA’ and correction of the poor antioxidant status. These and other concepts were reviewed at a symposium that organized at the 1998 World Gastroenterology Congress in Vienna by Dr. Braganza [92]. Another high point was the finding – in collaboration with Maurice Super and Martin Schwartz – of an increased frequency of mutations in the cystic fibrosis transmembrane regulator (CFTR) gene in patients with chronic pancreatitis [93]. She record the invaluable input during her 25-year “radical journey” of numerous scientists – in physiology (Maynard Case, Sigrid RuMeetishhauer), transplant immunology (Ian Hutchinson), surgical science (Anders Borgström), bacteriology (Louis Quesnel), pharmacy (Brian Houston, Martin Jones, John Fell, Frank Leach), biochemistry (Frank Steven, Jop Ubbink, Jessica Douglas, Lance Sandle, Iain Laing), pharmacogenetics (Jeffrey Idle), medical physics (Harbans Sharma), pathology (John Foster, Najeeb Haboubi, Iona Jeffrey), medical statistics (Linda Hunt, Roseanne McNamee, Chris Main), occupational health (Tim Lee, Ian Leck, Nicola Cherry), chemistry (Giocomo Sturniolo, George Smith, Philip Day), dietetics (Patricia Rose, Helen Worthington) and free radical pathology (Thomas Dormandy, John Gutteridge, John Butler) [94].

John A Williams
Dr John A Williams is one of the world’s leading physiologists working on signal transduction mechanisms in pancreatic acinar cells. He is worldwide recognized for his contribution to many areas of pancreatology, especially the understanding of GI hormone regulation of pancreatic exocrine function. Having grown up in a small college town in Washington state with an interest in science and natural history he aimed towards a career in medicine, in part because he received a lot of social reinforcement when he mentioned it. He took the chance to enter a summer research program prior to starting medical school at the University of Washington. By a somewhat convoluted logic he was placed in an electrophysiology laboratory and proceeded to fall in love with laboratory research, then took a year off to do research in the middle of medical school after which his mentor, J Walter Woodbury asked him if he wanted to take another year off and earn a PhD. His thesis was on the electrophysiology of the thyroid. He did a 2-year stint in the U.S. Public Health Service at NIH to fulfill my military obligation where he carried out research on thyroid secretion with Jan Woollf. They then moved to Cambridge in the UK where he worked in the laboratory of Keith Mathews adjacent to another postdoc, Ole Petersen, who had come from Copenhagen and was recording intracellularly from pancreas. It then became apparent to that the exocrine pancreas was an ideal tissue with which to study regulated secretion in that it was homogeneous with one predominant cell type and that there were simple assays to measure the enzymatic activity of the secretory products. Petersen and Williams carried out a still (2010) cited study showing the release of intracellular calcium and its relationship to secretion in perfused pancreatic segments stimulated with CCK-PZ. After an enjoyable stay in Cambridge, Williams moved to San Francisco where a faculty position was waiting. Over the first 5 years there, his research work shifted almost entirely to the pancreas. He was able to bridge his interests by studying the effects of insulin on acinar cells and the action of gastrointestinal hormones especially CCK on the exocrine pancreas [95].

References
1. Beger HG, Gansauge F. Master of surgery in Archiv für Klinische Chirurgie. Langenbecks Arch Surg 2010; 395 suppl 1: 17-21.
2. Bradley EL, Dexter ND. Management of severe acute pancreatitis: a surgical odyssey. Ann Surg 2010; 25: 6-17.
3. Leach SD, Gorelich FS, Modlin IM. Acute pancreatitis at its centenary. The contribution of Reginald Fitz. Ann Surg 1990; 212: 109-110.
4. Schnelltorfer T, Adams DB, Warshaw AL, Lillemoe KD, Sarr MG. Forgotten pioneers of pancreatic surgery: Beyond the favorite few. Ann Surg 2008; 247: 191-202.
5. Pannala R, Kidd M, Modlin IM: Acute pancreatitis: an historical perspective. Pancreas 2009; 38: 355-366.
6. Nordmann O. Neuere Anschauungen über die akute Pankreasnekrose und ihre Behandlung. Arch Klin Chir 1938; 193: 370-82.
7. Halsted WS. Retrojection of bile into the pancreas, a cause of acute hemorrhagic pancreatitis. Johns Hopkins Hosp Bull 1901; 12: 179-182.
8. Senn N. The Surgery of the Pancreas. Philadelphia, Dornan, 1886,71-107.
9. Rocha FG, Balakrishnan A, Ashley SW, Clancy TE. A historical perspective on the contributions of surgeons to the understanding of acute pancreatitis. Am J Surg 2008; 196: 442-429.
10. Schmieden V, Sebening W. Chirurgie des Pankreas. Arch Klin Chir 1927; 148: 319-387.
11. Siler VE, Wulsin JH. Consideration of the lethal factors in acute pancreatitis. Arch Surg 1951; 63: 496-504.
12. Walzel P. Zur Diagnose und Therapie der akuten Pankreasnekrose. Bruns’ Beitr 1929; 147: 3-13.
13. Morton J. Acute pancreatitis. Surgery 1945; 17: 475-491.
14. Demel R: Umstrittene Fragen bei akuter Pankreasnekrose. (Aktuelles zur Aetiologie, Diagnose und Behandlung der akuten Pankreasnekrose). Wien Klin Wochenschr 1936; 49: 1273-1278.
15. Paxton JR, Payne JH. Acute pancreatitis. A statistical review of 307 established cases of acute pancreatitis. Surg Gynecol Obstet 1948; 86: 69-75.
16. Watts GT. Total pancreatectomy for fulminant pancreatitis. Lancet 1963; 13: 384.
17. Edelmann G, Boutelier P. Le traitement des pancréatites aigües nécrosantes par l’ablation chirurgicale précoce des portions nécrosées. Chirurgie (Paris) 1974; 100: 155-167.
18. Leger L, Chiche B, Ghouti A. Notre expérience de la pancréatite aiguë. Chirurgie (Paris) 1977; 103: 846-847.
19. Mercadier M: Sur une série de 100 cas de pancréatite aiguë graves opérés précoce. Chirurgie (Paris) 1977; 103: 835-845.
20. Alexandre JH, Chambon H, Assan R. Total pancreatectomy in the treatment of acute necrotising and hemorrhagic pancreatitis. Indications – technique. Langenbecks Arch Chir 1976; 340: 231-247.
21. Kümmel E, Neher M, Schönborn H, Mangold G. Vorzeitig Operation bei akuter hämorrhagisch-nekrotisierender Pankreatitis. Dtsch Med Wochenschr 1975; 100: 2241-2245.
22. Neher M, Kümmel E, Mangold G, Schönborn H. Verzögerte Operation bei akuter Pankreatitis. Chirurg 1977; 48: 439-443.
23. Beger HG. Management of pancreatic necrosis and pancreatic abscess. In: Carter DC, Warshaw AL (eds): Pancreatitis. Edinburgh, Churchill Livingstone, 1989, vol 16, 107-19.
24. Elliott DW, Zollinger RM, Moore R, Ellison EH. The use of human serum albumin in the management of acute pancreatitis. Experimental and clinical observations. Gastroenterology 1955; 28: 563-587.
25. Elliott DW. Treatment of acute pancreatitis with albumin and whole blood. Arch Surg 1957; 75: 573-580.
26. Lankisch PG, Koop H, Winckler K, Quellhorst E, Schmidt H. Experimental model for peritoneal dialysis in small laboratory animals. Clin Nephrol 1975; 4: 251-252.
27. Lankisch PG, Koop H, Winckler K, Schmidt H. Continuous peritoneal dialysis as treatment of acute experimental pancreatitis in the rat. I. Effect on length and rate of survival. Dig Dis Sci 1979; 24: 111-116.
28. Amundsen E, Øfstad E, Hagen PO. Experimental acute pancreatitis in dogs. I. Hypotensive effect induced by pancreatic exudate. Scand J Gastroenterol 1968; 3: 659-664.
29. Satake K, Roziman JS, Appert HE, Carballo J, Howard JM. Hypotension and release of kinin-forming enzyme into ascitic fluid exudate during experimental pancreatitis in dogs. Ann Surg 1973; 177: 497-502.
30. Hagen PO, Øfstad E, Amundsen E. Experimental acute pancreatitis in dogs. IV. The relationship between phospholipase A and the histamine-releasing hypotensive effects of pancreatic exudate. Scand J Gastroenterol 1969; 4: 89-96.
31. Øfstad E, Amundsen E, Hagen PO. Experimental acute pancreatitis in dogs. II. Histamine release induced by pancreatic exudate. Scand J Gastroenterol 1969; 4: 75-79.
32. Lankisch PG, Koop H, Winckler K, Schmidt H. Continuous peritoneal dialysis as treatment of acute experimental pancreatitis in the rat. II. Analysis of its beneficial effect. Dig Dis Sci 1979; 24: 117-122.
33. Stone HH, Fabian TC. Peritoneal dialysis in the treatment of acute alcoholic pancreatitis. Surg Gynecol Obstet 1980; 150: 878-882.
34. Cooper MJ, Williamson RCN, Pollock AV. The role of peritoneal lavage in the prediction and treatment of severe acute pancreatitis. Ann Roy Coll Surg Engl 1982; 64: 422-425.
35. Kivilaakso E, Lemppinen M, Mäkeläinen A, Nikki P, Schröder T. Pancreatic resection versus peritoneal lavage for acute fulminant pancreatitis. Ann Surg 1984; 199: 426-431.
36. Mayer AD, McMahon MJ, Corfield AP, Cooper MJ, Williamson RCN, Dickson AP, Shearer MG, Imrie CW. Controlled clinical trial of peritoneal lavage for the treatment of severe acute pancreatitis. N Engl J Med 1985; 312: 399-404.
37. Ihse I, Evander A, Holmberg JT, Gustafson I. Influence of peritoneal lavage on objective prognostic signs in acute pancreatitis. Ann Surg 1986; 204: 122-127.
38. Teerenhovi O, Nordback I, Eskola J. High volume lesser sac lavage in acute necrotizing pancreatitis. Br J Surg 1989; 76: 370-373.
39. Ranson JHC, Berman RS. Long peritoneal lavage decreases pancreatic sepsis in acute pancreatitis. Ann Surg 1990; 211: 708-718.
40. Schröder T, Sainio V, Kivisaari L, Puolakkainen P, Kivilaakso E, Lemppinen M. Pancreatic resection versus peritoneal lavage in acute necrotizing pancreatitis. A prospective randomized trial. Ann Surg 1991; 214: 663-666.
41. Platell C, Cooper D, Hall JC. Acute pancreatitis: effect of somatostatin analogs and peritoneal lavage. A meta-analysis of peritoneal lavage for acute pancreatitis. J Gastroenterol Hepatol 2001; 16: 689-693.
42. Ballin G, Borgström A, Genell S, Ohlsson K: The effect of peritoneal lavage and aprotinin in the treatment of severe acute pancreatitis. Res Exp Med
1983; 183: 203-213.

43. Berling R, Borgström A, Ohlsson K. Peritoneal lavage with aprotinin in patients with severe acute pancreatitis. Effects on plasma and peritoneal levels of trypsin and leukocyte proteases and their major inhibitors. Int J Pancreatol 1998; 24: 9-17.

44. Arnold F, Doyle PJ, Bell G. Acute pancreatitis in a patient treated with cimetidine. Lancet 1978; 1: 382-383.

45. Hadas N, Wapnick S, Grosberg SJ, Sugaar S. Cimetidine induced mortality in experimental pancreatitis. Gastroenterology 1979; 76: 1148.

46. Evander A, Ihse I. Cimetidine treatment in acute experimental pancreatitis. Eur Surg Res 1980; 12: 301-309.

47. Lankisch PG, Koop H, Winckler K, Otto J. Cimetidine: harmful in acute experimental pancreatitis? Hepatogastroenterology 1982; 29: 195-197.

48. Morimoto T, Noguchi Y, Sakai T, Shimbo T, Fukui T. Acute pancreatitis and the role of histamine-2 receptor antagonists: a meta-analysis of randomized controlled trials of cimetidine. Eur J Gastroenterol Hepatol 2002; 14: 679-686.

49. Meschkinpour H, Molinari MD, Gardner L, Berk JE, Koehler FK. Cimetidine in the treatment of acute alcoholic pancreatitis. Gastroenterology 1979; 77: 687-690.

50. Siller C. Perez-Mateo M, Vazquez N, Martin A.: Controlled trial of cimetidine in acute pancreatitis. Eur J Clin Pharmacol 1981; 21: 17-21.

51. Broe PJ, Zinner MJ, Cameron JL. A clinical trial of cimetidine in acute pancreatitis. Surg Gynecol Obstet 1982; 154: 13-16.

52. Lojudice TA, Lang J, Metha H, Santa L. Treatment of acute alcoholic pancreatitis: the roles of cimetidine and nasogastric suction. Am J Gastroenterol 1984; 79: 553-558.

53. Navarro S, Ros E, Aused R, García-Pugés AM, Piqué JM, Vilar Bonet J. Comparison of fasting, nasogastric suction and cimetidine in the treatment of acute pancreatitis. Digestion 1984; 30: 224-230.

54. Cameron JL, Mehigan D, Zuidema GD. Evaluation of atropine in acute pancreatitis. Surg Gynecol Obstet 1979; 148: 206-208.

55. Knight MJ, Condon JR, Smith R. Possible use of glucagon in the treatment of pancreatitis. BMJ 1971; ii: 440-442.

56. Waterworth MW, Barbeazot GO, Hickman R., Terblanche J. A controlled trial of glucagon in experimental pancreatitis. Br J Surg 1976; 63: 617-620.

57. Condon RE, Woods JH, Poulin TL, Wagner WG, Pissiotis CA. Experimental pancreatitis treated with glucagon or lactated Ringer solution. Arch Surg 1974; 109: 154-158.

58. Lankisch PG, Winckler K, Bokermann M, Schmidt H, Creutzfeldt W. The influence of glucagon on acute experimental pancreatitis in the rat. Scand J Gastroenterol 1974; 9: 725-729.

59. Papp M, Ribet A, Fodor I, Németh Pé, Fehér S, Horváth JE, Folly G. Glucagon treatment of experimental acute pancreatitis. Acta Med Acad Sci Hung 1975; 32: 105-116.

60. Dürr HK, Weihe W, Bode C, Bode JC. A controlled trial of glucagon in acute experimental pancreatitis in rats. Z Gastroenterol 1977; 15: 728-733.

61. Manabe T, Steer ML. Experimental acute pancreatitis in mice. Protective effects of glucagon. Gastroenterology 1979; 76: 529-534.

62. Medical Research Council Multicentre Trial of Glucagon and Aprotinin: Death from acute pancreatitis. Lancet 1977; ii: 632-635.

63. Dürr HK, Maroske D, Zelder O, Bode JC. Glucagon therapy in acute pancreatitis. Report of a double-blind trial. Gut 1978; 19: 175-179.

64. Gauthier A, Gillet M, Di Costanzo J, Camelot G, Maurin P, Sarles H. Étude contrôlée multicentrique de l’aprotinine et du glucagon dans le traitement des pancréatites aiguës. Gastroenterol Clin Biol 1978; 2: 777-784.

65. Olazabal A, Fuller R. Failure of glucagon in the treatment of alcoholic pancreatitis. Gastroenterology 1978; 74: 489-491.

66. Debas HT, Hancock RJ, Soon-Shiong P, Smythe HA, Cassim MM. Glucagon therapy in acute pancreatitis: prospective randomized double-blind study. Can J Surg 1980; 23: 578-580.

67. Kronborg O, Bülow S, Joergensen PM, Svendsen LB. A randomized double-blind trial of glucagon in treatment of first attack of severe acute pancreatitis without associated biliary disease. Am J Gastroenterol 1980; 73: 423-425.

68. Medical Research Council Multicentre Trial: Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut 1980; 21: 334-339.

69. Schmidt H, Hesch R-D, Hüfner M, Paschen K, Creutzfeldt W. Hemmung der exokrinen Pankreassekretion des Menschen durch Calcitonin. Dtsch Med Wochenschr 1971; 96: 1173-1175.

70. Goebell H, Ammann R, Herfarth C, et al. A double-blind trial of synthetic salmon calcitonin in the treatment of acute pancreatitis. Scand J Gastroenterol 1979; 14: 881-889.

71. Paul F, Ohnhaus EE, Hesch RD, et al. Einfluß von Salm-Calcitonin auf den Verlauf der akuten Pankreatitis. Ergebnisse einer prospektiven Doppelblindstudie. Dtsch Med Wochenschr 1979; 104: 615-622.

72. Martinez E, Navarrete F. A controlled trial of synthetic salmon calcitonin in the treatment of severe acute pancreatitis. World J Surg 1984; 8: 354-359.

73. Smith M, Kocher HM, Hunt BJ. Aprotinin in severe acute pancreatitis. Int J Clin Pract 2010; 64: 84-92.

74. Trapnell JE, Rigby CC, Talbot CH, Duncan EHL. A randomized double-blind trial of Trasylol in the treatment of acute pancreatitis. Br J Surg 1974; 61: 177-182.

75. Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O’Neill J, Blungart LH. A single-centre double-blind trial of Trasylol therapy in
primary acute pancreatitis. Br J Surg 1978; 65: 337-341.
76. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas 1987; 2: 698-700.
77. Goebell H. Multicenter double-blind study of gabexate-mesilate (Foy), given intravenously in low dose in acute pancreatitis. Digestion 1988; 40: 83.
78. Büchler M, Malfertheiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993; 104: 1165-1170.
79. Messori A, Rampazzo R, Scroccaro G, et al. Effectiveness of gabexate mesilate in acute pancreatitis. A meta-analysis. Dig Dis Sci 1995; 40: 734-738.
80. Konttinen YP. Epsilon-aminocaproic acid in treatment of acute pancreatitis. Scand J Gastroenterol 1971; 6: 715-718.
81. Cuschieri A, Wood RAB, Cumming JRG, Meehan SE, Mackie CR. Treatment of acute pancreatitis with fresh frozen plasma. Br J Surg 1983; 70: 710-712.
82. Leese T, Holliday M, Heath D, Hall AW, Bell PRF. Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis. Br J Surg 1987; 74: 907-911.
83. Leese T, Thomas WM, Holliday M, et al. A multicentre controlled clinical trial of high-volume fresh frozen plasma therapy in prognostically severe acute pancreatitis. Ann Roy Coll Surg Engl 1991; 73: 207-214.
84. Mäkelä A, Kuusi T, Schröder T. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest 1997; 57: 401-408.
85. Lankisch PG, Koop H, Winckler K, Kunze H, Vogt W. Indomethacin treatment of acute experimental pancreatitis in the rat. Scand J Gastroenterol 1978; 13: 629-633.
86. Ebbehøj N, Friis J, Svendsen LB, Bülow S, Madsen P. Indomethacin treatment of acute pancreatitis. A controlled double-blind trial. Scand J Gastroenterol 1985; 20: 798-800.
87. Lankisch PG. Treatment of acute pancreatitis: an attempted historical review. Pancreatology 2010; 10: 134-141.
88. Eriksson S, Hagenfeldt L, Wahren J. A comparison of the effects of intravenous infusion of individual branched chain amino acids on blood amino acid levels in man. Clin Sci 1981; 60:95-100.
89. Braganza JM, Wickens D, Cawood P, Dormandy TL. Lipid peroxidation (free radical oxidation) products in bile from patients with pancreatic disease. Lancet 1983; II:375-379.
90. Braganza JM, Jolley JE, Lee WR. Occupational chemicals and pancreatitis: a link? Int J Pancreatol 1986; 1:9-19.
91. Kaneko T, Wang PY, Sato A. Enzymes induced by ethanol differently affect the pharmacokinetics of trichloroethylene and 1,1,1-trichloroethane. Occup Environ Med. 1994; 51(2): 113–119.
92. Braganza JM. A framework for the aetiogenesis of chronic pancreatitis. Digestion 1998; 59 (Suppl. 4):1-12.
93. Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998; 339 (3):645-652.
94. Fernández-Zapico ME. “Not knowing something is normally a milestone on the way to knowledge”. An interview with Joan M. Braganza. Pancreatology 2009; 9: 717-727.
95. Fernández-Zapico ME. Modeling a scientific career: an essential component of the mentorship process. An interview with John A Williams, professor of molecular and integrative physiology, University of Michigan, Ann Arbor, Mich., USA. Pancreatology 2010; 10: 1-3.